These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 34850547)

  • 1. Patient-derived organoids as a preclinical platform for precision medicine in colorectal cancer.
    Cho YW; Min DW; Kim HP; An Y; Kim S; Youk J; Chun J; Im JP; Song SH; Ju YS; Han SW; Park KJ; Kim TY
    Mol Oncol; 2022 Jun; 16(12):2396-2412. PubMed ID: 34850547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy.
    Narasimhan V; Wright JA; Churchill M; Wang T; Rosati R; Lannagan TRM; Vrbanac L; Richardson AB; Kobayashi H; Price T; Tye GXY; Marker J; Hewett PJ; Flood MP; Pereira S; Whitney GA; Michael M; Tie J; Mukherjee S; Grandori C; Heriot AG; Worthley DL; Ramsay RG; Woods SL
    Clin Cancer Res; 2020 Jul; 26(14):3662-3670. PubMed ID: 32376656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy.
    Mo S; Tang P; Luo W; Zhang L; Li Y; Hu X; Ma X; Chen Y; Bao Y; He X; Fu G; Xu X; Rao X; Li X; Guan R; Chen S; Deng Y; Lv T; Mu P; Zheng Q; Wang S; Liu F; Li Y; Sheng W; Huang D; Hu C; Gao J; Zhang Z; Cai S; Clevers H; Peng J; Hua G
    Adv Sci (Weinh); 2022 Nov; 9(31):e2204097. PubMed ID: 36058001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases.
    Weeber F; van de Wetering M; Hoogstraat M; Dijkstra KK; Krijgsman O; Kuilman T; Gadellaa-van Hooijdonk CG; van der Velden DL; Peeper DS; Cuppen EP; Vries RG; Clevers H; Voest EE
    Proc Natl Acad Sci U S A; 2015 Oct; 112(43):13308-11. PubMed ID: 26460009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical investigation of patient-derived cervical cancer organoids for precision medicine.
    Seol HS; Oh JH; Choi E; Kim S; Kim H; Nam EJ
    J Gynecol Oncol; 2023 May; 34(3):e35. PubMed ID: 36659831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective experimental treatment of colorectal cancer patients based on organoid drug responses.
    Ooft SN; Weeber F; Schipper L; Dijkstra KK; McLean CM; Kaing S; van de Haar J; Prevoo W; van Werkhoven E; Snaebjornsson P; Hoes LR; Chalabi M; van der Velden D; van Leerdam M; Boot H; Grootscholten C; Huitema ADR; Bloemendal HJ; Cuppen E; Voest EE
    ESMO Open; 2021 Jun; 6(3):100103. PubMed ID: 33887686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-derived cancer organoids for drug screening: Basic technology and clinical application.
    Ren X; Chen W; Yang Q; Li X; Xu L
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
    Xie BY; Wu AW
    Chin Med J (Engl); 2016 Oct; 129(20):2469-2475. PubMed ID: 27748340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Derived Organoid Model in the Prediction of Chemotherapeutic Drug Response in Colorectal Cancer.
    Hao M; Cao Z; Wang Z; Xin J; Kong B; Xu J; Zhang L; Chen P
    ACS Biomater Sci Eng; 2022 Aug; 8(8):3515-3525. PubMed ID: 35696669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids.
    Mao Y; Wang W; Yang J; Zhou X; Lu Y; Gao J; Wang X; Wen L; Fu W; Tang F
    Protein Cell; 2024 Apr; 15(4):285-304. PubMed ID: 37345888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.
    Votanopoulos KI; Mazzocchi A; Sivakumar H; Forsythe S; Aleman J; Levine EA; Skardal A
    Ann Surg Oncol; 2019 Jan; 26(1):139-147. PubMed ID: 30414038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organoid Cultures Derived From Patients With Papillary Thyroid Cancer.
    Chen D; Tan Y; Li Z; Li W; Yu L; Chen W; Liu Y; Liu L; Guo L; Huang W; Zhao Y
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1410-1426. PubMed ID: 33524147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of Using a Patient-Derived Tumor Organoid Culture Model to Predict the Response to Chemotherapy Regimens In Stage IV Colorectal Cancer: A Blinded Study.
    Wang T; Pan W; Zheng H; Zheng H; Wang Z; Li JJ; Deng C; Yan J
    Dis Colon Rectum; 2021 Jul; 64(7):833-850. PubMed ID: 33709991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.
    Cartry J; Bedja S; Boilève A; Mathieu JRR; Gontran E; Annereau M; Job B; Mouawia A; Mathias P; De Baère T; Italiano A; Besse B; Sourrouille I; Gelli M; Bani MA; Dartigues P; Hollebecque A; Smolenschi C; Ducreux M; Malka D; Jaulin F
    J Exp Clin Cancer Res; 2023 Oct; 42(1):281. PubMed ID: 37880806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma.
    Ramzy GM; Norkin M; Koessler T; Voirol L; Tihy M; Hany D; McKee T; Ris F; Buchs N; Docquier M; Toso C; Rubbia-Brandt L; Bakalli G; Guerrier S; Huelsken J; Nowak-Sliwinska P
    J Exp Clin Cancer Res; 2023 Apr; 42(1):79. PubMed ID: 37013646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer.
    Toshimitsu K; Takano A; Fujii M; Togasaki K; Matano M; Takahashi S; Kanai T; Sato T
    Nat Chem Biol; 2022 Jun; 18(6):605-614. PubMed ID: 35273398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.
    Ubink I; Bolhaqueiro ACF; Elias SG; Raats DAE; Constantinides A; Peters NA; Wassenaar ECE; de Hingh IHJT; Rovers KP; van Grevenstein WMU; Laclé MM; Kops GJPL; Borel Rinkes IHM; Kranenburg O
    Br J Surg; 2019 Sep; 106(10):1404-1414. PubMed ID: 31197820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studying cellular heterogeneity and drug sensitivity in colorectal cancer using organoid technology.
    Sasaki N; Clevers H
    Curr Opin Genet Dev; 2018 Oct; 52():117-122. PubMed ID: 30261425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciphering the Tumor Microenvironment of Colorectal Cancer and Guiding Clinical Treatment With Patient-Derived Organoid Technology: Progress and Challenges.
    Li J; Liu J; Xia W; Yang H; Sha W; Chen H
    Technol Cancer Res Treat; 2024; 23():15330338231221856. PubMed ID: 38225190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organoids as a Robust Preclinical Model for Precision Medicine in Colorectal Cancer: A Systematic Review.
    Flood M; Narasimhan V; Wilson K; Lim WM; Ramsay R; Michael M; Heriot A
    Ann Surg Oncol; 2022 Jan; 29(1):47-59. PubMed ID: 34596795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.